We Are One Seven LLC lifted its position in shares of Chemed Co. (NYSE:CHE) by 22.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,275 shares of the company’s stock after purchasing an additional 233 shares during the quarter. We Are One Seven LLC’s holdings in Chemed were worth $532,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Chemed by 2.5% during the second quarter. BlackRock Inc. now owns 1,697,275 shares of the company’s stock worth $612,445,000 after purchasing an additional 42,102 shares in the last quarter. FMR LLC lifted its position in Chemed by 27.0% in the 1st quarter. FMR LLC now owns 311,951 shares of the company’s stock valued at $99,847,000 after acquiring an additional 66,276 shares in the last quarter. Investec Asset Management LTD lifted its position in Chemed by 7.3% in the 2nd quarter. Investec Asset Management LTD now owns 269,948 shares of the company’s stock valued at $97,408,000 after acquiring an additional 18,449 shares in the last quarter. Invesco Ltd. lifted its position in Chemed by 7.4% in the 2nd quarter. Invesco Ltd. now owns 262,075 shares of the company’s stock valued at $94,567,000 after acquiring an additional 18,100 shares in the last quarter. Finally, TimesSquare Capital Management LLC lifted its position in Chemed by 27.9% in the 2nd quarter. TimesSquare Capital Management LLC now owns 217,000 shares of the company’s stock valued at $78,302,000 after acquiring an additional 47,300 shares in the last quarter. 87.12% of the stock is currently owned by institutional investors.
Several equities research analysts recently commented on the stock. Bank of America boosted their price objective on shares of Chemed from $470.00 to $500.00 and gave the company a “buy” rating in a research report on Friday, September 6th. ValuEngine cut shares of Chemed from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Royal Bank of Canada boosted their price objective on shares of Chemed to $405.00 and gave the company a “sector perform” rating in a research report on Monday, July 29th. Finally, Oppenheimer boosted their price objective on shares of Chemed from $400.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. Chemed has an average rating of “Hold” and a consensus target price of $411.25.
In other news, insider David Patrick Williams sold 17,979 shares of the business’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $430.80, for a total transaction of $7,745,353.20. Following the transaction, the insider now directly owns 34,850 shares in the company, valued at approximately $15,013,380. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George J. Walsh III acquired 500 shares of the stock in a transaction dated Wednesday, August 7th. The shares were purchased at an average price of $412.86 per share, for a total transaction of $206,430.00. Following the completion of the purchase, the director now directly owns 4,520 shares in the company, valued at $1,866,127.20. The disclosure for this purchase can be found here. Insiders have sold a total of 46,812 shares of company stock worth $20,005,507 over the last three months. Insiders own 3.96% of the company’s stock.
Shares of NYSE:CHE opened at $417.12 on Friday. The company’s 50-day moving average price is $422.58 and its two-hundred day moving average price is $371.75. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.81 and a quick ratio of 0.78. Chemed Co. has a one year low of $260.03 and a one year high of $441.79. The stock has a market capitalization of $6.51 billion, a PE ratio of 34.96, a price-to-earnings-growth ratio of 2.78 and a beta of 1.11.
Chemed (NYSE:CHE) last issued its quarterly earnings results on Thursday, July 25th. The company reported $3.36 EPS for the quarter, topping the consensus estimate of $3.09 by $0.27. Chemed had a net margin of 10.94% and a return on equity of 35.63%. The firm had revenue of $473.60 million for the quarter, compared to analysts’ expectations of $471.72 million. During the same period in the previous year, the firm posted $2.81 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, analysts anticipate that Chemed Co. will post 13.54 earnings per share for the current fiscal year.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
Featured Story: Why do companies issue convertible shares?
Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHE).
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.